Company intelligence / Profile preview

Akamis Bio

Cambridge, Massachusetts, United Statesakamisbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Akamis Bio has treated more than 200 patients across monotherapy and combination settings with checkpoint inhibitors. Their T-SIGn therapeutics have demonstrated a consistent safety and tolerability profile, with promising preliminary evidence of clinical activity. Their lead program NG-350A has shown proof-of-mechanism with evidence of tumor-selective delivery, replication, and transgene expression.

Therapeutic areas: Oncology
Modalities: Tumor gene therapyViral vector-based therapies
Industry: Biotech

Drug pipeline

5 assets

enadenotucirev

4 more assets in the full pipeline.

Request access →

Partnerships

MerckCancer Research Institute (CRI)Xuanzhu Biopharma

Beyond the preview

Go deeper on Akamis Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akamis Bio.

Explore the full profile